Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment

SARI İ., Birlik M., GÖNEN C., Akar S., GÜREL D., ÖNEN F., ...Daha Fazla

WORLD JOURNAL OF GASTROENTEROLOGY, cilt.14, sa.18, ss.2912-2914, 2008 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 18
  • Basım Tarihi: 2008
  • Doi Numarası: 10.3748/wjg.14.2912
  • Dergi Adı: WORLD JOURNAL OF GASTROENTEROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2912-2914
  • Anahtar Kelimeler: tumor necrosis factor alpha inhibitors, adverse effects, virus diseases, THERAPY, ANTIBODY, INFECTIONS, INFLIXIMAB
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Anti-tumor necrosis factor alpha (TNF-alpha) inhibitors are effective in the treatment of various inflammatory rheumatic conditions. Increased risks of serious infections are the major issues concerning the long-term safety of these agents. We present a case of a young male Behcet's patient whose disease was complicated by cytomegalovirus (CMV) colitis. Colitis started 10 d after the third Infliximab dose and responded to the cessation of TNF blocking treatment and administration of ganciclovir. Tumor necrosis factor alpha and interferon gamma act at several levels in combating viral infections. CMV infections should be kept in mind and included in the differential diagnosis of severe gastrointestinal symptoms in patients receiving anti-TNF agents. (C) 2008 WJG. All rights reserved.